Brazil’s IVD sector invited to table industry evidence for patient safety project
This article was originally published in Clinica
Executive Summary
Brazil’s in vitro diagnostic and laboratory supplies industry association, CBDL, has called on its members to help it collate feedback for a prospective government consultation on improving safety and service quality. CBDL has asked its members to submit feedback on three questions posed by healthcare products regulatory agency Anvisa: how can the CBDL contribute to the introduction of a national healthcare safety project; does such a project pose any risk or “negative impacts”; and are there any patient safety initiatives already in place? The CBDL is to participate in parliamentary discussions on the matter and is being invited to table details of specific patient safety initiatives already under way.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.